GlassScriptPhysician profile
Joselin Leyva
NPI 1770052797
$1,344.87
in general payments reported to CMS, 2019-2025
25 companies · $282 in 2025
The $282 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $68.42 · 2022: $335 · 2023: $334 · 2024: $325 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $768 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $767.91 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $584.22 | 2021-2025 | Rybrevant, Darzalex, Tecvayli |
| Incyte Corporation | $112.61 | 2022 | |
| Daiichi Sankyo INC. | $105.77 | 2024-2025 | Enhertu, Datroway |
| Merz North America, INC. | $90.19 | 2024 | |
| Merck Sharp & Dohme LLC | $51.84 | 2022-2023 | Dificid, Delstrigo |
| Tersera Therapeutics LLC | $40.51 | 2023-2025 | Zoladex |
| Adc Therapeutics America, INC. | $23.65 | 2024 | |
| Pfizer INC. | $22.62 | 2022 | |
| Janssen Scientific Affairs, LLC | $22.43 | 2023 | Darzalex |
| Immunogen, INC. | $21.92 | 2023 | Elahere |
| Sumitomo Pharma America, INC. | $21.56 | 2025 | Gemtesa |
| Genzyme Corporation | $21.31 | 2022 | |
| Pharmacosmos Therapeutics INC. | $21.27 | 2025 | Monoferric |
| Genmab U.S., INC. | $20.69 | 2023 | Epkinly |
| Regeneron Healthcare Solutions, INC. | $20.00 | 2025 | Lynozyfic |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Geron Corporation | $19.74 | 2024 | Rytelo |
| Glaxosmithkline, LLC. | $19.02 | 2023 | Trelegy Ellipta |
| Dova Pharmaceuticals | $18.82 | 2021 | |
| Jazz Pharmaceuticals INC. | $18.33 | 2025 | |
| Novartis Pharmaceuticals Corporation | $18.12 | 2021 | |
| Emd Serono, INC. | $15.79 | 2023 | Bavencio |
| Exeltis, USA INC. | $15.70 | 2023 | Slynd |
| Exact Sciences Corporation | $14.08 | 2023 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.57 | 2023 | Jardiance |
| Lilly USA, LLC | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joselin Leyva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.